The rationale for the combined use of genetically engineered biological drugs in patients with COVID-19


DOI: https://dx.doi.org/10.18565/pharmateca.2021.8.15-19

I.S. Burashnikova

Kazan State Medical Academy – Branch Campus of the Russian Medical Academy of Continuous Professional Education, Kazan, Russia, https://orcid.org/0000-0002-8511-5696
Currently, there are no clinical trial data to recommend the use of combinations of genetically engineered biological drugs in the treatment of patients with COVID-19. Clinical data on the sequential use of various genetically engineered biological drugs are contradictory. The combined use of genetically engineered biological drugs may increase the risk of suppression of the immune system. The use of Janus kinase inhibitors in combination with biological disease-modifying antirheumatic drug is not recommended.

Similar Articles


Бионика Медиа